Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013 - KALB-TV News Channel 5 & CBS 2

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, April 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013

http://www.reportbuyer.com/banking_finance/capital_markets/partnerships_licensing_investments_ma_deals_trends_pharmaceuticals_q4_2013.html

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q4 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the oil and gas industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2013 18
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2013 19
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2013 20
2.4.1 McKesson to Acquire Celesio for US$8.49 Billion 20
2.4.2 AstraZeneca to Acquire Remaining 50% Interest in Diabetes Joint Venture from Bristol-Myers Squibb for US$4.3 Billion 22
2.4.3 Shire Completes Acquisition of Majority Interest in ViroPharma for US$2.7 Billion 23
2.4.4 Johnson & Johnson Prices Public Offering of Notes for US$3.5 Billion 24
2.4.5 OncoMed Pharma Enters Into Co-Development Agreement with Celgene 24
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 26
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2013 26
3.1.1 Top M&A Deals in Q4 2013 27
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2012 - Q4 2013 28
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2013 30
3.2.1 Top Initial Public Offerings in Q4 2013 32
3.2.2 Top Secondary Offerings in Q4 2013 32
3.2.3 Top PIPE Deals in Q4 2013 32
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2012-Q4 2013 33
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2012 - Q4 2013 34
3.2.6 Top Venture Financing Deals in Q4 2013 36
3.2.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2013 37
3.2.8 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2013 38
3.2.9 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2012 - Q4 2013 39
3.2.10 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2012 - Q4 2013 41
3.2.11 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2012 - Q4 2013 43
3.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2013 44
3.3.1 Top Private Equity Deals in Q4 2013 45
3.3.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2012 - Q4 2013 46
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2013 48
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2013 48
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2012 - Q4 2013 50
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 52
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2013 53
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2013 54
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2013 55
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 56
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2012 - Q4 2013 58
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2012 - Q4 2013 59
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 61
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2013 63
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2013 63
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 65
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2013 67
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2013 67
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2013 68
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2012 - Q4 2013 69
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2012 - Q4 2013 71
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2012 - Q4 2013 73
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2012 - Q4 2013 74
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2012 - Q4 2013 76
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 78
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2012 - Q4 2013 78
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2012 - Q4 2013 80
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2012 - Q4 2013 82
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2012 - Q4 2013 84
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2012 - Q4 2013 86
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q4 2012 - Q4 2013 88
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2012 - Q4 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2013 92
7.1.1 Oncology - Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2013 97
7.2.1 Central Nervous System - Deals of the Quarter 99
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2013 101
7.3.1 Infectious Disease - Deals of the Quarter 103
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2013 104
7.4.1 Immunology - Deals of the Quarter 106
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2013 107
7.5.1 Metabolic Disorders - Deals of the Quarter 109
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2013 111
7.6.1 Cardiovascular - Deals of the Quarter 113
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2013 115
7.7.1 Gastrointestinal - Deals of the Quarter 117
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2013 119
7.8.1 Dermatology - Deals of the Quarter 121
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2013 122
7.9.1 Respiratory - Deals of the Quarter 124
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2013 126
7.10.1 Ophthalmology - Deals of the Quarter 128
8 Deal Summary by Geography 129
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2013 129
8.1.1 North America - Deals of the Quarter 131
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2013 134
8.2.1 Europe - Deals of the Quarter 136
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2013 139
8.3.1 Asia-Pacific - Deals of the Quarter 141
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2013 143
8.4.1 Rest of the World - Deals of the Quarter 145
9 Pharmaceuticals & Healthcare, Global, Top Advisors 146
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 146
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 148
10 Appendix 150
11 Further Information 154
11.1 Methodology 154
11.2 About GlobalData 155
11.3 Disclosure information 156
11.4 Disclaimer 156

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2012 - Q4 2013 17
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2013 19
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2013 20
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 27
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2013 27
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2012 - Q4 2013 29
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2012 - Q4 2013 31
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2013 32
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2013 32
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2013 32
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2012-Q4 2013 33
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2012 - Q4 2013 34
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 36
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2013 36
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2013 38
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2012 - Q4 2013 40
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 42
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2012 - Q4 2013 43
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 45
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2013 45
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2012 - Q4 2013 47
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 49
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 51
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 53
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 53
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2013 54
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2013 55
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2012 - Q4 2013 57
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2012 - Q4 2013 60
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2012 - Q4 2013 62
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 64
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 66
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2013 67
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2013 67
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2013 68
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 70
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2012 - Q4 2013 72
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2012 - Q4 2013 75
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Ther+apy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2012 - Q4 2013 77
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2012 - Q4 2013 79
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2012 - Q4 2013 81
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2012 - Q4 2013 83
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q4 2012 - Q4 2013 85
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2012 - Q4 2013 87
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q4 2012 - Q4 2013 89
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2012 - Q4 2013 91
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 93
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 98
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 102
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 105
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 108
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 112
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 116
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 120
Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 123
Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 127
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 130
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 135
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 140
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 144
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2013 - Q4 2013 147
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2013 - Q4 2013 149
Table 63: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q4 2012-Q4 2013 150

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2012 - Q4 2013 15
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2013 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2013 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2012 - Q4 2013 26
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2012 - Q4 2013 28
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 30
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2012 - Q4 2013 34
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 35
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2013 37
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2013 38
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2012 - Q4 2013 39
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 41
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 44
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2012 - Q4 2013 46
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 48
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 50
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2012 - Q4 2013 52
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2012 - Q4 2013 56
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2012 - Q4 2013 58
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2012 - Q4 2013 59
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2012 - Q4 2013 61
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 63
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 65
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 69
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 71
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2012 - Q4 2013 73
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2012 - Q4 2013 74
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2012 - Q4 2013 76
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2012 - Q4 2013 78
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2012 - Q4 2013 80
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2012 - Q4 2013 82
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2012 - Q4 2013 84
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2012 - Q4 2013 86
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q4 2012 - Q4 2013 88
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2012 - Q4 2013 90
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 92
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 97
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 101
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 104
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 107
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 111
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 115
Figure 43: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 119
Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 122
Figure 45: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 126
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 129
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 134
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 139
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2012 - Q4 2013 143
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2013 - Q4 2013 146
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2013 - Q4 2013 148


Read the full report:
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2013

http://www.reportbuyer.com/banking_finance/capital_markets/partnerships_licensing_investments_ma_deals_trends_pharmaceuticals_q4_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KALB. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.